The Molecular Immunology Center (CIM) announced today that the regulatory authority for medicines, equipment and medical devices in Cuba approved the Health Register conditional of Cuban product NeuroEpofor patients with mild and moderate Alzheimer’s disease.
Through Twitter, the scientific institution announced that this condition will be valid for three years, and is established for the presentation of the results of a confirmatory phase III clinical efficacy study.
The general director of the CIM, Eduardo Ojito, pointed out in the same social network that this constitutes a magnificent result of Cuban science.
It is a nasal formulation of recombinant Erythropoietin (EPO) with low sialic acid content, an isoform with a similar composition to natural EPO that is produced in the central nervous system.
The phase II-III clinical trial showed that treatment with NeuroEPO for 48 weeks was safe and well tolerated, there were no serious adverse events, and a good part of the patients showed a reduction in the progression of cognitive deterioration and improvement of secondary variables.
In addition, cerebral perfusion in the parieto-temporal region improved, and 72 percent of treated patients stabilized global electroencephalogram values.
There are only six drugs in the world to alleviate the effects of the disease, and all of them are extremely expensive, with treatments that can exceed up to 80,000 dollars a year.
According to CIM specialists, the application of NeuroEPO is being evaluated to treat other diseases, such as ataxia, Parkinson’s, ischemic strokes, and the sequelae of COVID-19.
